Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients with Hepatocellular Carcinoma. Nicole E Rich , Ju Dong Yang , Ponni V Perumalswami , Naim Alkhouri , Whitney Jackson , Neehar D Parikh , Neil Mehta , Reena Salgia , Andres Duarte-Rojo , Laura Kulik , Mina Rakoski , Adnan Said , Omobonike Oloruntoba , George N Ioannou , Maarouf A Hoteit , Andrew M Moon , Amol S Rangnekar , Sheila L Eswaran , Elizabeth Zheng , Janice H Jou , James Hanje , Anjana Pillai , Ruben Hernaez , Robert Wong , Steven Scaglione , Hrishikesh Samant , Devika Kapuria , Shaun Chandna , Russell Rosenblatt , Veeral Ajmera , Catherine Frenette , Sanjaya K Satapathy , Parvez Mantry , Prasun Jalal , Binu V John , Oren K Fix , Michael Leise , Christina C Lindenmeyer , Avegail Flores , Nayan Patel , Z Gordon Jiang , Nyan Latt , Renumathy Dhanasekaran , Mobolaji Odewole , Sofia Kagan , Jorge A Marrero , Amit G Singal Clinical Gastroenterology and Hepatology（2020）
摘要
Based on a survey sent to hepatology providers, there is variation in provider attitudes and practice patterns regarding use and timing of DAAs for patients with HCC. Further studies are needed to characterize the risks and benefits of DAA therapy in this patient population.
更多 查看译文
关键词
Liver Cancer, HCV, TACE, Drug
AI 理解论文
溯源树
样例
